Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Angela Kay Berry

Doris Riether

Renee M Zindell

Eugene R Hickey

David S Thomson

Monika Ermann

Innocent Mushi

Nigel James Blumire

Pier Francesco Cirillo

Lifen Wu

Alessandra Bartolozzi

James Edward Jenkins

Todd Bosanac

Christopher Francis Palmer

Someina Khor

Achim Sauer

Michael Jason Burke

Can Mao

Stephen East

Fariba Soleymanzadeh

Wang Mao

Joerg Bentzien

Darren Todd Disalvo

Patricia Amouzegh

Yue Shen

Malcolm Taylor

Markus Ostermeier

Shuang Liang

Joshua Courtney Horan

Niklas Heine

Thierry Bouyssou

Hidenori Takahashi

Tina Marie Morwick

Dirk Gottschling

Zhonghua Zhang

Zhidong Chen

Michel Jose Emmanuel

Stephane De Lombaert

Matthew Russell Netherton

Pui Leng Loke

Rajashekhar Betageri

John David Ginn

Maolin Yu

Sabine K Schlyer

Chuk Chui Man

John A Westbrook

Michael J Burke

Stephen Peter East

Eugene Richard Hickey

Tamara Denise Hopkins

Chandana Parke

Chandana Chowdhury

David Smith Thomson

Joerg Martin Bentzien

The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Rto R, Rto R, Y and A are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Inhibitors of TRPC6

The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Heteroaromatic compounds as BTK inhibitors

The present invention encompasses compounds of the formula (I) wherein the groups R, Cy, and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use. 

Pyrazole compounds as BTK inhibitors

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. 

Compounds which modulate the CB2 receptor

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R, R, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Biarylamide inhibitors of leukotriene production

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Heterocyclic compounds which modulate the CB2 receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R-Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Soluble guanylate cyclase activators

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain (I). 

Pyrrolidine compounds which modulate the CB2 receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. 

Therapeutic uses of compounds which selectively modulate the CB2 receptor

Growing community of inventors

Gaylordsville, CT, United States of America

Angela Kay Berry